Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 16 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

6 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
6(66.7%)
N/A
3(33.3%)
9Total
Phase 4(6)
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials
NCT06692088Not Yet Recruiting

"Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment"

Role: lead

NCT03476473Unknown

Early Detection of Respiratory Disorders in Psychosis

Role: lead

NCT03481465Unknown

Searching for Early Biomarkers of Long-term Hepatic, Metabolic and Endothelial Dysfunction in Non-affective Psychosis

Role: lead

NCT02200588Unknown

Longitudinal Long-term Study (10 Years) of the Sample of First Episode of Non-affective Psychosis: PAFIP

Role: lead

NCT02897167Completed

Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia Patients

Role: lead

NCT02532491Phase 4Unknown

Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up

Role: lead

NCT02858102Not ApplicableUnknown

Impact of Aerobic Exercise on Metabolic Syndrome, Neurocognition and Empowerment in Individuals With Mental Disorders

Role: lead

NCT02205437Unknown

Novel Candidate Genes for Treatment Response to Antipsychotics in Schizophrenia

Role: lead

NCT02916303Unknown

Cost-effectiveness of Interventions in First-episode Psychosis

Role: lead

NCT03883204Phase 4Unknown

Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up

Role: lead

NCT03090490Not ApplicableUnknown

10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals

Role: lead

NCT03090503Phase 4Unknown

Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up

Role: lead

NCT02526030Phase 4Completed

Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up

Role: lead

NCT02220504Not ApplicableCompleted

3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals

Role: lead

NCT02534363Phase 4Completed

Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up

Role: lead

NCT02305823Phase 4Completed

Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis

Role: lead

All 16 trials loaded